Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired PneumoniaJudith Marín‐Corral, Peter Chipev, Sergi Pascual-Guàrdia et al.|CHEST Journal|2020Cited by 56
Immunologic resilience and COVID-19 survival advantageGrace C. Lee, Maritza Garza, Marcos I. Restrepo et al.|Journal of Allergy and Clinical Immunology|2021Cited by 47
Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence studyManuela Carugati, Simone Aranha Nouér, Stefano Aliberti et al.|European Journal of Clinical Microbiology & Infectious Diseases|2020Cited by 34
Empirical antibiotic therapy improves outcomes in mechanically ventilated patients with COVID-19: An emulated targeted trial within a prospective, multicentre cohort studyPedro David Wendel‐Garcia, Ángel Sánchez-Miralles, Albert Gabarrús et al.|Journal of Infection|2025Cited by 3
4221 Lower Serum TWEAK Concentration is a Biomarker for Mortality in Community Acquired PneumoniaDaniela Parra-Tanoux, Luis Felipe Reyes, Manuela Sáenz-Valcárcel et al.|Journal of Clinical and Translational Science|2020Cited by 0